Ehmet Health Strengthens Partnership with Jiaxing Proton Oncology Center

Michael Teicher, CEO of Ehmet Health, and Daniel Schoettlin, Director of Quality and Regulatory Affairs, traveled to Jiaxing for an in-depth week long exchange with Jiaxing Proton Oncology Center and FNC Investment. The delegation focused on strengthening business collaboration, aligning government-enterprise initiatives, and promoting innovation in proton therapy.

Jiaxing Proton Cancer Hospital, FNC Investment and Ehmet Health Symposium

Meetings included discussions with local government leaders on the hospital’s strategic role in providing high-quality cancer care while easing the treatment burden for patients. Key topics covered included accelerator performance upgrades, treatment room optimization, and the integration of specialized breast cancer treatment equipment, including Ehmet Health’s MammoKnife system.

Representatives of the three parties discussed the drawing plan

Ehmet Health engaged in multiple rounds of consultations with project partners to refine cooperation models, architectural planning, and implementation strategies.

Michael Teicher and Daniel Schoettlin of Ehmet Health pictured with Tang Chun, general manager of Jiaxing Proton Cancer Hospital

Cultural experiences, from traditional Hangzhou palace feasts to strolls through Jiangnan water towns, strengthened international friendship and collaboration.

This visit lays a solid foundation for future joint efforts, supporting the advancement of proton therapy and enhanced patient outcomes in China and globally.